Protagonist Therapeutics, Inc.
PTGX NASDAQHealthcare ★★★★★Latest Earnings
Date
Aug 5, 2026
ET
EPS Est.
2.27
EPS Actual
2.29
Revenue Est.
$212M
Revenue Actual
$213.5M
Next Earnings Report
Date
Nov 5, 2026 · Thu
Time
Time TBD
Fiscal Period
FY2026 Q3
EPS Est.
2.19
Revenue Est.
$219.9M
Company Overview
Protagonist Therapeutics, Inc. (ticker PTGX) is listed on NASDAQ with a market cap of about $9.92B. Its next earnings report (FY2026 Q3) is expected on Nov 5, 2026 (ET), Time TBD, with consensus EPS of 2.19. In the last 15 reported quarters, EPS beat consensus estimates 9 times.
Actual EPS TrendRecently15Term · Mar 15, 2023 → Aug 5, 2026
Mar 15, 2023Range: -0.69 ~ 3.26Aug 5, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 5, 2026 | -- | 2.27 | 2.29 | $212M | $213.5M |
| May 5, 2026 | -- | -0.65 | Above forecast↑0.05 | $11.7M | $56.4M |
| Feb 25, 2026 | -- | -0.53 | Below forecast↓-0.69 | $8.7M | $7.4M |
| Nov 6, 2025 | -- | -0.59 | -0.62 | $14.9M | $4.7M |
| Aug 6, 2025 | -- | -0.53 | -0.55 | $8.4M | $5.5M |
| May 6, 2025 | -- | -0.50 | Above forecast↑-0.19 | $6.6M | $28.3M |
| Feb 21, 2025 | -- | 0.06 | Above forecast↑1.98 | $81M | $170.6M |
| Nov 7, 2024 | -- | -0.59 | -0.54 | $38.8M | $4.7M |
| Aug 6, 2024 | -- | -0.50 | -0.50 | $8M | $4.2M |
| May 7, 2024 | -- | 1.19 | Above forecast↑3.26 | $120M | $255M |
| Feb 27, 2024 | -- | 0.03 | Above forecast↑0.44 | $40M | $60M |
| Nov 2, 2023 | -- | -0.68 | -0.58 | $38.3M | -- |
| Aug 3, 2023 | -- | -0.65 | -0.68 | $8.3M | -- |
| May 4, 2023 | -- | -0.69 | -0.67 | $2M | -- |
| Mar 15, 2023 | -- | -0.67 | -0.69 | $5M | -- |
Original Filings (SEC)
10-Q2026-08-05 ↗
8-K2026-08-05 ↗
8-K2026-06-18 ↗
10-Q2026-05-05 ↗
8-K2026-05-05 ↗
10-K2026-02-25 ↗
8-K2026-02-25 ↗
8-K2026-01-12 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
